Clinical Trial Search

Primary: Percentage of Participants With Disease Progression or Death — 66.9 percentage of participants

Primary: Changes in Haemoglobin Concentration From Day 3 Post Treatment of Malaria Episode to Day 90 in the Weekly Chloroquine and Placebo Arms — 93.4; 93.7 g/L

Primary: Duodenal Villus Height:Crypt Depth — 2.73; 2.73 Ratio — p=0.693

Primary: Change From Baseline in MADRS Total Score at Week 8 — -19.36; -18.16 units on a scale — p=0.199

Primary: Percentage of Participants Achieving American College of Rheumatology 20 (ACR 20) Response — 10.9; 19.1; 24.4; 39.1 percentage of participants

Primary: Percentage of Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group Who Are Seizure Free for 26 Consecutive Weeks of Treatment During the Evaluation…

Primary: Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After Completion of All Study Therapy (SVR24) — 92.0; 96.2 percentage of participants — p=<0.001

Primary: Disease-Free Survival (DFS) — 78.6 percentage of patients

Primary: Incidence of Adverse Drug Reactions During 7-day Treatment of uUTI Symptoms With Canephron® N — 0 Adverse Drug Reactions

Primary: Complete Response Rate — 0 percentage of subjects

Primary: Subject Attrition Post Randomization — 1; 2; 1; 1 participants

Primary: Depression Residual Symptom Scale — 21.8 units on a scale — p=<0.05

Primary: Long Term Safety — 22 participants

Primary: Exhaled Nitric Oxide (FeNO) Level — 29.3; 23.3 ppb

Primary: Prorated AUC of Total Fatigue as Measured by the Brief Fatigue Inventory (BFI) at Baseline and at Weeks 1-4 — 50.33; 47.15 units on a scale — p=0.317